(Q107101650)

https://api.crossref.org/v1/works/http://dx.doi.org/10.1038/nbt1189-1163

4 June 2021

title

Enhanced Fibrinolysis by a Bispecific Monoclonal Antibody Reactive to Fibrin and Tissue Plasminogen Activator (English)

1 reference

4 June 2021

1 reference

Tomofumi Kurokawa

1

1 reference

https://api.crossref.org/v1/works/http://dx.doi.org/10.1038/nbt1189-1163

https://api.crossref.org/v1/works/http://dx.doi.org/10.1038/nbt1189-1163

4 June 2021

Susumu Iwasa

series ordinal

2

1 reference

https://api.crossref.org/v1/works/http://dx.doi.org/10.1038/nbt1189-1163

4 June 2021

Atsushi Kakinuma

series ordinal

3

1 reference

https://api.crossref.org/v1/works/http://dx.doi.org/10.1038/nbt1189-1163

4 June 2021

publication date

21 October 2013

1 reference

4 June 2021

1 reference

https://api.crossref.org/v1/works/http://dx.doi.org/10.1038/nbt1189-1163

https://api.crossref.org/v1/works/http://dx.doi.org/10.1038/nbt1189-1163

4 June 2021

volume

7

1 reference

https://api.crossref.org/v1/works/http://dx.doi.org/10.1038/nbt1189-1163

4 June 2021

issue

11

1 reference

https://api.crossref.org/v1/works/http://dx.doi.org/10.1038/nbt1189-1163

4 June 2021

page(s)

1163-1167

1 reference

Specific lysis of an iliofemoral thrombus by administration of extrinsic (tissue-type) plasminogen activator

4 June 2021

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNBT1189-1163

7 January 2021

Recombinant tissue plasminogen activator (rt-PA): is it the thrombolytic agent of choice for an evolving acute myocardial infarction?

1 reference

https://api.crossref.org/works/10.1038%2FNBT1189-1163

7 January 2021

Comparison of two dose regimens of intravenous tissue plasminogen activator for acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1038%2FNBT1189-1163

7 January 2021

Monoclonal antibodies to a synthetic fibrin-like peptide bind to human fibrin but not fibrinogen

1 reference

https://api.crossref.org/works/10.1038%2FNBT1189-1163

7 January 2021

Antibody-enhanced thrombolysis: targeting of tissue plasminogen activator in vivo

1 reference

https://api.crossref.org/works/10.1038%2FNBT1189-1163

7 January 2021

Characterization of functional domains in human tissue-type plasminogen activator with the use of monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1038%2FNBT1189-1163

7 January 2021

Hybrid hybridoma producing a bispecific monoclonal antibody that can focus effector T-cell activity

1 reference

https://api.crossref.org/works/10.1038%2FNBT1189-1163

7 January 2021

Bispecific antibody-producing hybrid hybridoma and its use in one-step immunoassays for human lymphotoxin

1 reference

https://api.crossref.org/works/10.1038%2FNBT1189-1163

7 January 2021

Bispecific antibody-producing hybrid hybridomas selected by a fluorescence activated cell sorter

1 reference

https://api.crossref.org/works/10.1038%2FNBT1189-1163

7 January 2021

Hybrid hybridomas and the production of bi-specific monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1038%2FNBT1189-1163

7 January 2021

Human extrinsic plasminogen activator fibrinolytic properties and neutralization in vivo

1 reference

https://api.crossref.org/works/10.1038%2FNBT1189-1163

7 January 2021

Two-step targeting of urokinase to plasma clot provides efficient fibrinolysis

1 reference

https://api.crossref.org/works/10.1038%2FNBT1189-1163

7 January 2021

A simple method for polyethylene glycol-promoted hybridization of mouse myeloma cells

1 reference

https://api.crossref.org/works/10.1038%2FNBT1189-1163

7 January 2021

Selective cytotoxicity of drug-monoclonal antibody conjugates against murine bladder tumor cells

1 reference

https://api.crossref.org/works/10.1038%2FNBT1189-1163

7 January 2021

Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4

1 reference

https://api.crossref.org/works/10.1038%2FNBT1189-1163

7 January 2021

Thrombolysis with human extrinsic (tissue-type) plasminogen activator in rabbits with experimental jugular vein thrombosis. Effect of molecular form and dose of activator, age of the thrombus, and route of administration

1 reference

https://api.crossref.org/works/10.1038%2FNBT1189-1163

7 January 2021

https://api.crossref.org/v1/works/http://dx.doi.org/10.1038/nbt1189-1163

Identifiers

1 reference